Adjuvant chemotherapy for endometrial cancer after hysterectomy

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 10, 2011, Pages

  Johnson, Nick ^a   Bryant, Andrew ^b   Miles, Tracie ^a   Hogberg, Thomas ^c   Cornes, Paul ^d  

^a ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CASE STUDY; CAUSE OF DEATH; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SPECIFIC SURVIVAL; ENDOMETRIUM CANCER; FOLLOW UP; HUMAN; HYSTERECTOMY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ENDOMETRIUM TUMOR; FEMALE; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80155143528     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003175.pub2     Document Type: Review

References (104)

1. Kristensen G. A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high risk endometrial carcinoma [EORTC 55991]. http://groups.eortc.be/gcg/studyprotocols.htm#55991. http://groups.eortc.be/gcg/studyprotocols.htm#55991.
2. Maggi R, Cagnazzo G, Atlante G, Marinaccio M. Risk groups and adjuvant therapy in surgical staged endometrial cancer patients. A randomized multicentre study comparing chemotherapy with radiation therapy. International Journal of Gynecological Cancer. 1999; Vol. 99;9 Suppl 1:85 Abstract B73.
3. Maggi R, Cucchi L, Restelli C, Delzotti F, Frigoli A. Post surgical treatment of endometrial cancer [GICOG trial]. International Journal of Gynecological Cancer 2005;93(3 Suppl 1):46, Abstract 166.
4. Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al.Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. British Journal of Cancer 2006;95(3):266-71.
5. Bruner DW, Barsevick A, Tian C, Randall M, Mannel R, Cohn DE, et al.Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Quality of Life Research: an international journal of quality of life aspects of treatment, care and rehabilitation 2007;16(1):89-100.
6. Randall ME. ASCO media player [Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group]. http://media.asco.org/asco/meetings_education/vm/2003/slides_only/frame.asp, 2003.
7. Randall ME, Brunetto G, Muss H, Mannel RS, Spirtos N, Jeffrey F, Thigpen JT, Benda J. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group. Proceedings of the American Society of Clinical Oncology. 2003; Vol. 22:2. Abstract 3.
8. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al.Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2006;24(1):36-44.
9. Thomas G. ASCO media player [Plenary Session (Dr Thomas critiquing GOG 122)]. http://media.asco.org/asco/meetings_education/vm/2003/slides_only/frame.asp.
10. Watkins Bruner D, Barsevick A, Tian C, Randall M, Mannel R, Cohn D, et al.Quality of life trade-off to incremental gain in survival on Gynecologic Oncology Group (GOG) Protocol 122: Whole abdominal irradiation (WAI) vs. doxorubicin-platinum (AP) chemotherapy in advanced endometrial cancer. Proceedings of the American Society of Clinical Oncology. 2003; Vol. 22:449, Abstract 1803.
11. GOG Protocol FAQ. http://www.gog.org/protocolfaq.html.
12. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al.A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecologic Oncology 2007;107(2):177-85.
13. Morrow CP, Bundy B, Creasman W, Homesley H. A randomized study of adriamycin adjuvant chemotherapy for patients with high-risk stage I and II (occult) endometrial carcinoma: a GOG study. Proceedings, International Gynecological Cancer Society: Amsterdam, the Netherlands. 1987:87.
14. Morrow CP, Bundy BN, Homesley HD, Creasman WT, Hornback NB, Kurman R, et al.Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: A Gynecologic Oncology Group Study. Gynecologic Oncology 1990;36(2):166-71.
15. Sagae S, Udagawa Y, Susumu N, Niwa K, Kudo R, Nozawa S. JGOG2033: Randomized phase III trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma. Proceedings of the American Society of Clinical Oncology.2005: 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005. Orlando, Florida, 2005; Vol. Abstract 5002, issue http://media.asco.org/player/default.aspx?, :http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=34&trackID=5&sessionID=701.
16. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al.Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecologic Oncology 2008;108(1):226-33.
17. Kuoppala T, Maenpaa J, Tomas E, Puistola U, Salmi T, Grenman S, et al.Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol 2008;110(2):190-5.
18. Hogberg T, Signorelli M, Freire de Oliveira C, Fossati R, Lissoni AA, Sorbe B, et al.Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - Results from two randomised studies. European Journal of Cancer 2010;46(13):2422-31.
19. Hogberg T. Case #4 Endometrial CarcinomaStage IIIC. http://www.primeoncology.org/Files/Doc/SLIDES/EPGM06282008/Case4.pdf. 2008.
20. Hogberg T, Rosenberg P, Kristensen G, de Oliveira CF, de Pont Christensen R, Sorbe B, et al.A randomized phase-III study on adjuvant treatment with radiation (RT) chemotherapy (CT) in early-stage high-risk endometrial cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Abstracts of the 43rd Annual Meeting of the American Society of Clinical Oncology; 1-5 June 2007; Chicago, Illinois. www.asco.org, 2007; Vol. Part I.2007;25 (18 Suppl):Abstract 5503.
21. Hogberg T, Signorelli M, Freire de Oliveira C, Fossati R, Lissoni AA, Sorbe B, et al.Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - Results from two randomised studies. European Journal of Cancer 2010;46(13):2422-31.
22. Hogberg, T. [Presentation: A randomized phase-III study on adjuvant treatment with radiation (RT) 177; chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991)]. ASCO media player, Oral Presentation Gynecologic Cancer Track. 2007; Vol. Abstract No: 5503:http://media.asco.org/player/default.aspx.
23. Hogberg T, Signorelli M, Freire de Oliveira C, Fossati R, Lissoni AA, Sorbe B, et al.Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - Results from two randomised studies. European Journal of Cancer 2010; Vol. 46, issue 13:2422-31.
24. Kristensen G. Endometrial cancer [33rd ESMO Congress]. http://www.esmo.org/fileadmin/media/presentations/977/1739/Endometrial%20cancer%20GBK.ppt.pdf. Stockholm, 2006.
25. Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg MEL, Poveda A et al on behalf of the EORTC-GCCG. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC-GCCG. Annals of Oncology 2003;14:441-8.
26. Bruner DW, Barsevick A, Tian C, Randall M, Mannel R, Cohn DE, et al.Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study. Quality of Life Research 2007;16(1):89-100.
27. Brunetto V, Kilgore L, Soper J, McGehee R, Olt G, Lentz SS, et al.A phase III trial of ifosfamide alone or in combination with cisplatin in the treatment of advanced, persistent or recurrent carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecologic Oncology 2000;98;68(1):137, Abstract 266.
28. Chauvergne J, Cappelaere P, Durand M, Brunet R, Hoerni B. Chemotherapy of cervico-uterin carcinoma by two associations:cisplatine or detorubicine. Results of a comparative controlled trial. Bulletin du cancer 2008;81;68(2):363.
29. Cohen CJ, Bruckner HW, Deppe G, Blessing JA, Homesley H, Lee JH, et al.Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Obstetrics and Gynecology 1984;63(5):719-26.
30. Deng XH, Duan W, Li BZ. Estramustine phosphate in the treatment of endometrium carcinoma. Chinese Journal of Cancer Research 2000;12(1):58-63.
31. Edmonson JH, Krook JE, Hilton JF, Malkasian GD, Everson LK, Jefferies JA, et al.Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecologic Oncology 1887;28(1):20-4.
32. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al.Phase III trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2004;22(11):2159-66.
33. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Vaccarello L, Gallion H. Phase III randomised trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in ednometrial carcinoma: a Gynecologic Oncology Group study. Annals of Oncology 2004;15:1173-8.
34. Fujimura H, Kikkawa F, Oguchi H, Nakashima N, Mizutani S. Adjuvant chemotherapy including cisplatin in endometrial carcinoma. Gynecologic & Obstetric Investigation 2000;50(2):127-32.
35. Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, et al.Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrence endometrial carcinaoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2003;21(20):3808-13.
36. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al.Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2004;22(11):2159-66.
37. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al.Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. Journal of Clinical Oncology 2004;22(19):3902-8.
38. GOG Protocol FAQ. http://www.gog.org/protocolfaq.html.
39. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al.Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2007;25(5):526-31.
40. GOG Protocol FAQ. http://www.gog.org/protocolfaq.html.
41. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T, et al.Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. International Journal of Radiation Oncology, Biology, Physics. 2004;59(1):168-73.
42. Horton J, Begg CB, Arseneault J, Bruckner H, Creech R, Hahn RG. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treatment Report 1978;62(1):159-61.
43. Long HJ, Nelimark RA, Cha SS. Comparison of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) vs doxorubicin and cisplatin (AC) in advanced endometrial carcinoma (Meeting abstract). Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1995; Vol. 14:282, Abstract 797.
44. Omura GA, Blessing JA, Major F, Silverberg S. A randomized trial of adriamycin versus no adjuvant chemotherapy in stage I and II uterine sarcomas. Proceedings of the American Society of Clinical Oncology. 1985; Vol. 83 (2):149, Abstract C-580.
45. Pawinski A, Tumolo S, Hoesel G, Cervantes A, van Oosterom AT, Hoctin Boes G, et al.Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomised phaseII study of the EORTC Gynecological Cancer Cooperative Group. European Journal of Obstetrics and Gynecology and Reproductive Biology 1999;86:179-83.
46. Samuels BL, Rushing D, Chawla SP, Schuetze SM, Von Mehren M, Keohan ML, et al.Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients with leiomyosarcomas or liposarcomas refractory to conventional doxorubicin and ifosfamide chemotherapy. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 23:814, Abstract 9000..
47. Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, et al.A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecologic Oncology 2000;79(2):147-53.
48. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Journal of Clinical Oncology 1994;12(7):1408-14.
49. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al.Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group Study (GOG). Journal of Clinical Oncology 2004;22(19):3902-8.
50. Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer. http://clinicaltrials.gov/ct2/show/NCT00807768.
51. http://www.cancer.gov/clinicaltrials/ft-GOG-0249.
52. GOG 0258 (RTOG 1073 Endorsed). A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin andPaclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma. http://www.rtog.org/LinkClick.aspx?fileticket=7aqw-i1bTZ8%3D&tabid=331.
53. Thomas Hogberg, MMC-08-03-060, NCT01041027. Is the sequential combination of RT after four courses of CT better then 2 additional courses of CT in the adjuvant therapy of high-risk endometrial cancer. A Phase III intergroup trial on adjuvant therapy in radically operated endometrial cancer patients with high risk for micro-metastatic disease: 4 courses of adjuvant CT (CT) followed by radiation therapy (RT) versus 2 more courses of CT.
54. CKTO-2006-04ISRCTN14387080, CKTO-PORTEC-3, EU-20664, NCT00411138. Phase III Randomized Study of Concurrent Chemoradiotherapy Followed By Adjuvant Chemotherapy Versus Pelvic Radiotherapy Alone in Patients With High-Risk Stage IB-III Endometrial Carcinoma Alternate Title. Chemotherapy and Radiation Therapy Compared With Radiation Therapy Alone in Treating Patients With High-Risk Stage I, Stage II, or Stage III Endometrial Cancer.
55. Abu-Rustum NR, Zhou Q, Gomez JD Alektiar KM, Soslow RA, Levine DA, et al.A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecologic oncology 2010;116(3):399-403.
56. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Treatment modalities in endometrial cancer. Current Opinion in Oncology 2007;19(5):479-85.
57. Aoki Y, Watanabe M, Amikura T. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecologic Oncology 2004;94:333-9.
58. Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. Journal of Clinical Oncology 2004;15(22):2461-8.
59. Cheong KA, Chrystal K, Harper PG. Adjuvant chemotherapy in non-small cell lung cancer. International Journal of Clinical Practice 2007;611(1):143-6.
60. Williams C, Quinn G, Jess C, Bishop T, Hayes J. Cochrane Gynaecological Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs) [Art. No.: GYNAECA]. Cochrane Database of Systematic Reviews 2010, issue 2. [http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/GYNAECA/].
61. Creutzberg C. Adjuvant Chemotherapy for Endometrial Cancer. International Journal of Gynecological Cancer 2010;20(11):S60-S63.
62. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). BMJ Publication Group, 2001.
63. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
64. Fehr MK, Streich MS. The validity of chemotherapy in the treatment of endometrial cancer (German). Gynakologisch-Geburtshilfliche Rundschau 2006;46(1-2):34-8.
65. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5, version 2.0. Lyon: IARCPress, 2004.
66. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008 [GLOBOCAN 2008]. International Journal of Cancer 2010;127(12):2893-917.
67. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD005390.pub2].
68. Gadducci A, Tana R, Cosio S, Genazzani AR. Adjuvant treatment in endometrial cancer. Ginecologia y Obstetricia de Mexico 2007;3(1):1-7.
69. Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006812].
70. Gelber RD, Cole BF, Goldhirsch A, Bonadonna G, Howell A, McArdle CS, et al.Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer Journal from Scientific American 1995;1(2):114-21.
71. Sutton GP, Blessing JA, Barrett RJ, Soper JT, McGehee R, Olt G, et al.Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology 1992;166(2):556-9.
72. Reisinger SA, Asbury R, Liao SY, Homesley HD. A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma. Gynecologic Oncology 1996;63(3):299-303.
73. Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, et al.Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecologic Oncology 2005;97(3):755-63.
74. Green JA, Kirwan JJ, Tierney J, Vale CL, Symonds PR, Fresco LL, et al.Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD002225.pub2].
75. Hayakawa S, Sato S, Takano T, Wagazuma S, Yajima A. Chemotherapy of uterine endometrial cancer [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1995;22(9):1169-75.
76. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
77. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008.
78. Hirai M, Hirono M, Oosaki T. Adjuvant chemotherapy in stage I uterine endometrial carcinoma. International Journal of Gynaecology and Obstetrics 2002;78:37-44.
79. Hogberg T. Adjuvant Chemotherapy in Endometrial Carcinoma: Overview of Randomised Trials. Clinical Oncology 2008;20(6):463-9.
80. Humber C, Tierney J, Symonds P, Collingwood M, Kirwan J, Williams C, et al.Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003915.pub3].
81. UK-improving outcomes guidance. Guidance on Commissioning Cancer Services Improving Outcomes in Gynaecological Cancers The Manual. http://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc4-8f.pdf. Vol. Catalogue number 16149, London SE1 8UG: NHS Executive Health Services Directorate Wellington House London SE1 8UG. July 1999. NHS Executive Health Services Directorate Wellington House, July 1999..
82. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer (systematic review and meta-analysis). BJOG 2007;141(11):1313-20.
83. Kodama J, Seki N, Ojima Y. Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2007;131(1):76-80.
84. Hayakawa S, Sato S, Takano T, Wagazuma S, Yajima A. Chemotherapy of uterine endometrial cancer. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1995;95;22(9):1169-75.
85. Kong A, Johnson N, Cornes P, Simera I, Collingwood M, Williams C, et al.Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD003916.pub2].
86. Lee CM, Szabo A, Shrieve DC, Macdonald OK, Gaffney DK. Frequency and Effect of Adjuvant Radiation Therapy Among Women With Stage I Endometrial Adenocarcinoma. JAMA 2006;295:389-97.
87. Lukka H, Chambers A, Fyles A, Thephamongkhol K, Elit L, Fung-Kee-Fung M, et al. Adjuvant Radiotherapy in Women with Stage I Endometrial Cancer: A Clinical Practice Guideline. A Quality Initiative of the Program in Evidence-based Care (PEBC) [Cancer Care Ontario Report]. http://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc4-10f.pdf March 9, 2006.
88. Luoma ML, Hakamies-Blomqvist L, Sjöström J, Mouridsen H, Pluzanska A, Malmström P, et al.Physical performance, toxicity, and quality of life as assessed by the physician and the patient. Acta Oncologica 2002;41(1):44-9.
89. Martin-Hirsch PPL, Jarvis GG, Kitchener HC, Lilford R. Progestagens for endometrial cancer. Progestagens for endometrial cancer. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD001040].
90. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer.. Cochrane Database of Systematic Reviews 2010, Issue Issue 1. Art. No.: CD007585. DOI: 10.1002/14651858.CD007585.pub2. [DOI: 10.1002/14651858.CD007585.pub2;:].
91. Miller DS, King LP. Gynecologic oncology group trials in uterine corpus malignancies: recent progress. Journal of Gynecologic Oncology 2008;19(4):218-22.
92. National Cancer Institute, USA. http://www.cancer.gov/.
93. National Comprehensive Cancer Network. http://www.nccn.org/clinical.asp.
94. Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clinical Advances in Hematology & Oncology 2006;4(6):459-68.
95. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
96. Piver MS, Lele SB, Marchetti DL, Emrich LJ. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. Journal of Surgical Oncology 2006;38(4):233-9.
97. Rodriguez AO. Chemotherapy for early stage endometrial cancer? Should we be using it?. Current Opinion in Obstetrics & Gynecology 2008;20(1):1-3.
98. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7th Edition. Wiley-Blackwell, 2009.
99. Stanojevic Z, Djordjevic B, Todorovska I, Lilic V, Zivadinovic R, Dunjic O. Risk factors and adjuvant chemotherapy in the treatment of endometrial cancer. Journal of B.U.ON 2008;13(1):23-30.
100. Thomas G. ASCO media player [Plenary Session (Dr Thomas critiquing GOG 122); A Randomized Trial of WAI vs. A/P in Advanced Endometrial CA.]. http://media.asco.org/asco/meetings_education/vm/2003/slides_only/frame.asp.
101. Tierney J. Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration (NACCCMA) Collaboration. Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD001774.pub2].
102. van Nes JG, Nortier WR, van de Velde CJ. The 4th large meta-analysis of all trials of the treatment of operable breast cancer: increased survival after a longer follow-up][Article in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2005;149(26):1978-80.
103. Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgical) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD004706.pub3].
104. World Health Organization. International Statistical Classification of Diseases and Related Health Problems [World Health Organization classification of disease]. 10th Revision Version. WHO, 2007.